PLATE 00 / ABOUT
A reading bench, not a clinic.
KLOW Clinic is an independent editorial project. It publishes summaries of the peer-reviewed research on KPV, BPC-157, GHK-Cu, and TB-500. It is not a medical clinic, it does not employ clinicians, it does not provide medical advice, and it does not sell, manufacture, or distribute any peptide or product.
What KLOW Clinic is
KLOW Clinic is an independent editorial project that publishes summaries of the peer-reviewed research literature on the KLOW four-peptide research blend (KPV + BPC-157 + GHK-Cu + TB-500) and on each of its individual components. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any peptide or any other product. Our work is editorial commentary on publicly available science — a quiet reading bench for a small body of literature that is otherwise scattered across vendor catalogs, rodent-model journals, and community forums.
The 'clinic' in the domain name is editorial framing. It describes the position the publisher occupies relative to the literature — a research-context reading room organized the way a peptide-research reference clinic might be — not a representation that the publisher operates a medical practice, sees patients, or dispenses substances. This distinction is load-bearing. KLOW Clinic does not provide consultations, does not write prescriptions, does not staff a pharmacy, and does not engage with individual research subjects.
Editorial standards
Every numbered claim on the site cites a peer-reviewed paper, a systematic review, a regulatory document, or a public clinical-trial record. The citations are listed on /references with DOIs and links to PubMed, PMC, or the publisher. We restrict citations to PubMed, PMC, ClinicalTrials.gov, FDA labels and bulk-drug-substance lists, NIH publications, and peer-reviewed journals. We avoid citing vendor literature, community forums, or unsourced summaries. Where the published literature is genuinely thin — as it is for the four-peptide KLOW combination itself — we say so plainly and we do not fill the gap with extrapolation.
The site uses a four-color component taxonomy throughout: sage for KPV, sky blue for BPC-157, warm tan for GHK-Cu, coral for TB-500. This is a navigation aid, not a clinical claim. Each component's color also appears beside its citation entries on /references so readers can quickly find the literature for a specific peptide. The combination-evidence-gap card and the dashed-outline diorama tile that appear across the site mark the absence of any controlled four-peptide combination study; this absence is editorially structural, not decorative.
Regulatory framing of the KLOW blend
All four components in the KLOW blend are research peptides. None is approved by the U.S. Food and Drug Administration for any human indication. The blend itself has no FDA approval as a combination product. BPC-157 and TB-500 were placed on the FDA's Category 2 list of bulk drug substances of safety concern in September 2023, effectively prohibiting 503A and 503B compounding; both were removed from Category 2 in April 2026 following nomination withdrawal, but neither was moved to Category 1 (permitted for compounding), leaving them in a regulatory gray zone. BPC-157, TB-500, and KPV-related bulk drug substances are scheduled for FDA Pharmacy Compounding Advisory Committee evaluation on July 23 and 24 of 2026 [1].
TB-500 is explicitly prohibited at all times by the World Anti-Doping Agency under category S2. BPC-157 is listed under WADA category S0 effective 2022. GHK-Cu and KPV are not currently named on the WADA prohibited list, but athletes subject to WADA testing should treat the KLOW blend as prohibited because of its BPC-157 and TB-500 content.
What we do not do
We do not employ doctors, pharmacists, nurse practitioners, or any other clinical staff, and the publisher does not represent itself as a member of any such profession. We do not provide medical advice; nothing on this site should be construed as a recommendation to administer any peptide to any human or animal subject. We have nothing to supply — no peptide, no blend, no compounded preparation passes through this domain. We do not maintain a physical clinic, a laboratory, a pharmacy, a compounding facility, or any other regulated premises. We do not interlink with other portfolio sites, and we do not promote a parent vendor or telehealth program from here.
What remains, after all those subtractions, is the whole of what KLOW Clinic is: an editorial reading bench for four component literatures and the empty fifth tile between them. The summaries are the work, the citations are the evidence, and the laboratory-only framing of these peptides is a fact we report rather than a transaction we facilitate.